#156429

IDH1 Mutant Glioma Xenograft (JHH-273) mouse

Cat. #156429

IDH1 Mutant Glioma Xenograft (JHH-273) mouse

Cat. #: 156429

Sub-type: Mouse

Availability: 6-8 weeks

Disease: Glial tumor formation

Model: Mutant

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Gregory Riggins

Institute: Johns Hopkins University

Tool Details
Handling
Target Details
References

Tool Details

*FOR RESEARCH USE ONLY

  • Tool name: IDH1 Mutant Glioma Xenograft (JHH-273) mouse
  • Research fields: Cancer;Drug development
  • Tool sub type: Mouse
  • Disease: Glial tumor formation
  • Model: Mutant
  • Description: An in vivo Isocitrate Dehydrogenase (IDH-1) glioma mouse xenograft model has been developed to further study effective therapies for IDH mutations characterized by increased DNA methylation and production of the common oncometabolite, 2-HG. Difficult grafting cell-culture techniques and current engineered cell line quality have limited additional laboratory studies; however, this model was developed directly from a WHO grade III- glial cell positive cancer patient tissue (JHH273) with a confirmed IDH mutation through DNA sequencing and maintains IDH-1 mutation features observed in human primary glial brain tumors. Additionally, when models were exposed to a demethlyating agent, 5-azacytidine, a reduction in methylation and tumor growth was observed opening the door for more clinical analysis. This model meets a critical need to test drug agents targeting mechanisms involved in glial tumor formation.
  • Genetic background: 4–6-week old female athymic nude mice
  • Phenotype: 4–6-week old female athymic nude mice

Handling

  • Shipping conditions: Embryo/Spermatoza- Dry Ice

Target Details

  • Target: IDH1

References

  • Borodovsky et al. 2013. Oncotarget. 4(10):1737-47. PMID: 24077805.